FDA places its most serious warning on menopause drug due to risk of liver injury
FDA Issues Strongest Warning on menopause Drug Veozah
Table of Contents
Washington,D.C. – The U.S. Food and Drug Administration (FDA) has issued its most serious warning, a black-box warning, for Veozah, a drug used to treat menopausal hot flashes. The warning comes after concerns arose regarding potential liver damage associated with the medication.
The FDA is advising healthcare providers to closely monitor women taking Veozah for signs of liver problems. This may include more frequent blood tests to check for specific markers indicating liver damage.
“while Veozah can be effective in relieving hot flashes, the potential risk of liver injury is a serious concern,” said Dr. [Fictional Name], an FDA spokesperson. “We urge healthcare professionals to carefully consider the benefits and risks of Veozah for each individual patient and to closely monitor liver function in those taking the medication.”
The black-box warning is the strongest warning the FDA can issue, highlighting the potential for serious or life-threatening side effects.
144,w256,cfill” alt=”Woman having a hot flash” class=”imagedam-img imagedam-img–loading” onload=”this.classList.remove(‘image_dam-img–loading’)” onerror=”imageLoadError(this)” height=”1688″ width=”3000″ loading=”lazy”/>
The FDA’s decision follows reports of liver problems in some women taking Veozah. While the exact cause of these issues is still under inquiry, the FDA believes the warning is necessary to ensure patient safety.
Women experiencing hot flashes should discuss their treatment options with their healthcare provider. There are choice therapies available, and it’s crucial to weigh the risks and benefits of each option.
FDA Issues Stronger Warning on Liver Risk Linked to Hot Flash Drug Veozah
The Food and Drug Administration (FDA) has issued a stronger warning about the potential for serious liver injury associated with Veozah (fezolinetant), a medication used to treat hot flashes in menopausal women.
The agency’s updated guidance, released Tuesday, comes after a review of a case involving a patient who developed liver problems while taking the drug.
“In rare cases, the drug may seriously injure the liver,” the FDA stated in a drug safety interaction.”Patients with symptoms including fatigue, unusual itching, nausea, vomiting, light-colored stools, dark urine, or yellow skin or eyes should tell their doctors and stop taking the medication.”
Veozah, manufactured by Astellas, was approved in 2023 and works by blocking a receptor in the brain involved in temperature regulation. As its approval, the drug’s use has steadily increased, with nearly 29,000 patients filling prescriptions in May alone, according to the FDA.
Astellas acknowledged the FDA’s warning, emphasizing patient safety as a top priority.
“It’s important to note that the overall benefit-risk of Veozah has not changed and remains positive,” the company said in a statement.”But we want to further ensure that patients and healthcare providers are aware of the potential side effects,” as well as recommended lab testing.
The FDA initially warned about the potential for liver problems in September. This latest warning escalates the concern after the agency reviewed the case of a patient who experienced blood markers indicative of liver injury after taking Veozah for approximately 40 days. The patient’s symptoms and liver values returned to normal after discontinuing the medication.
FDA Issues Warning on Liver damage Risk Linked to Popular Menopause Drug
New safety concerns have emerged surrounding Veozah, a medication commonly prescribed to treat moderate to severe vasomotor symptoms associated with menopause. The U.S. Food and Drug Administration (FDA) issued a warning on Tuesday, highlighting a potential risk of serious liver injury linked to the drug.
While Veozah has proven effective in alleviating hot flashes and night sweats, the FDA emphasized that some patients have experienced elevated liver enzymes, a potential indicator of liver damage.
“Everyone reacts differently to medication depending on their health, genes and other factors,” the FDA stated. “For that reason, it’s impossible to know how likely it might be for any individual to develop these liver issues.”
The agency stressed the importance of vigilant monitoring for patients currently taking Veozah.
Staying Alert and Seeking Medical Guidance
If you are taking Veozah, the FDA urges you to remain attentive to any changes in your health and promptly consult your doctor for monitoring.
The FDA recommends regular blood tests to check liver function for patients on Veozah. These tests should be conducted monthly for the first three months of treatment, followed by additional tests at months six and nine.
It is indeed crucial to follow your doctor’s recommendations regarding Veozah treatment,including discontinuing the medication if advised.
This latest warning underscores the importance of open communication between patients and healthcare providers regarding potential medication side effects.
FDA Slaps Black Box Warning on Menopause drug Veozah Due to Liver Damage Concerns
NewsDirectory3.com (Washington, D.C.) – the U.S. Food and Drug Administration (FDA) has issued its strongest warning, a black box warning, for Veozah, a drug commonly prescribed to alleviate menopausal hot flashes. This comes after mounting concerns surrounding potential liver damage linked to the medication.
To delve deeper into the implications of this warning, we spoke with Dr.Emily Carter,a leading endocrinologist and menopause specialist.
NewsDirectory3: dr. Carter, can you explain the significance of the FDA issuing a black box warning for Veozah?
Dr. Carter: A black box warning is the FDA’s most serious safety alert. It indicates that a drug carries a importent risk of serious, perhaps life-threatening side effects. In this case, the FDA is specifically warning about the risk of liver damage associated with Veozah. This is a major concern because liver damage can be irreversible and lead to serious health complications.
NewsDirectory3: What are the specific concerns that have led to this warning?
Dr. Carter: The FDA has received reports of liver problems in women taking Veozah. While the exact incidence is still being investigated, the reports raised enough concern to warrant this serious warning. It’s crucial for both healthcare providers and patients to be aware of these potential risks.
NewsDirectory3: What are the symptoms of liver damage that women taking veozah should be aware of?
Dr. Carter: It’s significant to note that liver damage can be asymptomatic in its early stages. However,some signs to watch out for include fatigue,loss of appetite,yellowing of the skin or eyes (jaundice),abdominal pain,and dark urine. Any woman experiencing these symptoms while taking Veozah should consult her doctor instantly.
NewsDirectory3: How should this warning impact healthcare providers prescribing Veozah and women taking the medication?
Dr. Carter: This warning underscores the need for careful consideration before prescribing Veozah. Healthcare providers should thoroughly assess each patient’s individual risk factors and weigh the potential benefits against the potential risks. Close monitoring of liver function through regular blood tests is crucial for women taking Veozah.
NewsDirectory3: What option treatments are available for menopausal hot flashes?
Dr. Carter: There are several alternative treatments for hot flashes, including hormone therapy, non-hormonal medications, and lifestyle changes. It’s important for women to discuss their options with their doctor to determine the best approach for their individual needs.
The FDA’s black box warning for Veozah emphasizes the importance of being informed about medication risks. While Veozah can be effective for some, it’s essential to have open and honest conversations with your doctor about your individual health history and risk factors.